BIOA BioAge Labs posts narrower Q4 2025 loss than expected shares fall 11 percent today RFAI RF outlines upcoming strategic acquisition targets in its latest quarterly earnings release Xenon Pharmaceuticals XENE Unveils Robust Azetukalner Phase III Data Q3 NDA Filing Plans at Bloom Burton Conference